Atea Pharmaceuticals (AVIR) News Today → Does this make you sick? (From Allegiance Gold) (Ad) Free AVIR Stock Alerts $3.63 -0.02 (-0.55%) (As of 01:55 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 2:17 AM | americanbankingnews.comWilliam Blair Equities Analysts Reduce Earnings Estimates for Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)May 18 at 2:17 AM | americanbankingnews.comAtea Pharmaceuticals, Inc. to Post Q2 2024 Earnings of ($0.79) Per Share, Leerink Partnrs Forecasts (NASDAQ:AVIR)May 17 at 7:50 AM | marketbeat.comQ2 2024 EPS Estimates for Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Lowered by AnalystAtea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) - Equities researchers at Leerink Partnrs lowered their Q2 2024 earnings per share estimates for shares of Atea Pharmaceuticals in a research report issued on Tuesday, May 14th. Leerink Partnrs analyst R. Ruiz now forecasts that the company wMay 17 at 5:48 AM | americanbankingnews.comAnalyzing Atea Pharmaceuticals (NASDAQ:AVIR) & Akebia Therapeutics (NASDAQ:AKBA)May 17 at 5:06 AM | americanbankingnews.comAtea Pharmaceuticals, Inc. Expected to Post Q1 2025 Earnings of ($0.60) Per Share (NASDAQ:AVIR)May 16, 2024 | marketbeat.comResearch Analysts Set Expectations for Atea Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:AVIR)Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) - Equities research analysts at William Blair issued their Q1 2025 earnings estimates for Atea Pharmaceuticals in a report issued on Wednesday, May 15th. William Blair analyst T. Lugo anticipates that the company will post earnings of ($0.60)May 16, 2024 | markets.businessinsider.comAtea Pharmaceuticals: Assessing Bemnifosbuvir’s Prospects Amidst Clinical and Financial ChallengesMay 16, 2024 | investing.comAtea Pharmaceuticals Inc (AVIR)May 15, 2024 | msn.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2024 Earnings Call TranscriptMay 15, 2024 | finance.yahoo.comAtea Pharmaceuticals Inc (AVIR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...May 14, 2024 | investorplace.comAVIR Stock Earnings: Atea Pharmaceuticals Misses EPS for Q1 2024May 14, 2024 | msn.comAtea Pharmaceuticals GAAP EPS of -$0.75 misses by $0.14May 14, 2024 | finance.yahoo.comAtea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 12, 2024 | americanbankingnews.comAtea Pharmaceuticals (AVIR) to Release Earnings on TuesdayMay 7, 2024 | finance.yahoo.comAtea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024April 29, 2024 | finanznachrichten.deAtea Pharmaceuticals, Inc.: Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024April 29, 2024 | globenewswire.comAtea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024April 24, 2024 | marketbeat.comBML Capital Management LLC Grows Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)BML Capital Management LLC lifted its stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 13.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,462,079 shares of the company's stock after acquApril 9, 2024 | marketbeat.comStonepine Capital Management LLC Trims Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)Stonepine Capital Management LLC trimmed its stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 51.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 839,514 shares of the company's stock afMarch 27, 2024 | globenewswire.comAtea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk PatientsMarch 21, 2024 | edition.cnn.comAtea Pharmaceuticals, Inc.March 16, 2024 | finance.yahoo.comAVIR Apr 2024 2.500 callMarch 5, 2024 | marketbeat.comFmr LLC Cuts Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)Fmr LLC trimmed its position in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 24.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,452,550 shares of the company's stoMarch 3, 2024 | finance.yahoo.comAVIR Mar 2024 7.500 callMarch 1, 2024 | markets.businessinsider.comAtea Pharmaceuticals: Balancing Promising Prospects with Clinical and Regulatory RisksMarch 1, 2024 | finanznachrichten.deAtea Pharmaceuticals, Inc.: Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 29, 2024 | finance.yahoo.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | marketbeat.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Down 57.4% in FebruaryAtea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report) saw a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 1,620,000 shares, a decline of 57.4% from the January 31st total of 3,800,000 shares. Approximately 2.2% of the shares of the company are sold short. Based on an average trading volume of 473,900 shares, the days-to-cover ratio is currently 3.4 days.February 28, 2024 | benzinga.comRecap: Atea Pharmaceuticals Q4 EarningsFebruary 28, 2024 | finance.yahoo.comAtea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial ResultsFebruary 28, 2024 | globenewswire.comAtea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 21, 2024 | finance.yahoo.comAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024February 21, 2024 | globenewswire.comAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024February 13, 2024 | stockhouse.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Atea Pharmaceuticals, Inc. (AVIR) and Encourages Investors to Contact the FirmFebruary 7, 2024 | marketbeat.comAtea Pharmaceuticals, Inc. Forecasted to Earn Q1 2024 Earnings of ($0.66) Per Share (NASDAQ:AVIR)Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for shares of Atea Pharmaceuticals in a report issued on Monday, February 5th. Leerink Partnrs analyst R. Ruiz expects that the company will post earnings per shFebruary 3, 2024 | marketbeat.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) CAO Sells $47,911.68 in StockAtea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report) CAO Wayne Foster sold 12,477 shares of the firm's stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $3.84, for a total value of $47,911.68. Following the completion of the transaction, the chief accounting officer now owns 20,857 shares of the company's stock, valued at approximately $80,090.88. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.January 15, 2024 | marketbeat.comShort Interest in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Expands By 7.1%Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 3,770,000 shares, a growth of 7.1% from the December 15th total of 3,520,000 shares. Approximately 5.1% of the company's stock are short sold. Based on an average daily volume of 413,000 shares, the short-interest ratio is currently 9.1 days.January 10, 2024 | finance.yahoo.comAtea Pharma (AVIR) Gains on Upbeat Initial Data From HCV StudyJanuary 9, 2024 | msn.comAtea Pharmaceuticals' Hepatitis C Virus Candidate Shows EfficacyJanuary 9, 2024 | msn.comAtea gains after mid-stage data for lead asset in Hepatitis CJanuary 8, 2024 | finance.yahoo.comAtea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19January 6, 2024 | morningstar.comAtea Pharmaceuticals Inc Ordinary SharesJanuary 6, 2024 | morningstar.comAtea Pharmaceuticals Inc Ordinary SharesJanuary 3, 2024 | finance.yahoo.comAtea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 1, 2024 | marketbeat.comBML Capital Management LLC Grows Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)BML Capital Management LLC grew its stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 114.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,800,000 shares of the company's stock after acquirNovember 13, 2023 | finance.yahoo.comAtea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023November 9, 2023 | finance.yahoo.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.comQ3 2023 Atea Pharmaceuticals Inc Earnings CallNovember 8, 2023 | msn.comAtea Pharmaceuticals GAAP EPS of -$0.40November 8, 2023 | finance.yahoo.comAtea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Warren Buffett's "mystery stock" (Ad)WARNING: Read This Before the Next Fed Meeting Investors are looking to the Fed with high hopes for interest rate relief. Unfortunately, many have no idea there's another major story unfolding right now, one that could be worth $40 trillion. This Wall Street millionaire just stepped forward with all the details, and how it could make some AVIR Media Mentions By Week AVIR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVIR News Sentiment▼0.050.42▲Average Medical News Sentiment AVIR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVIR Articles This Week▼231▲AVIR Articles Average Week Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Verastem News ADC Therapeutics News Precigen News Kamada News Nkarta News Nektar Therapeutics News Nanobiotix News Erasca News Atai Life Sciences News Mersana Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVIR) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsThis Could be Your “Big Money” AI MomentInvestorPlaceDigitizing the $11T commodities sector with one tiny stockResource Stock DigestObama’s Forever Term [exposed]Porter & CompanyNew Options need New Trading StrategiesNetpicks Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
